A Phase 2 interventional study of Ticagrelor Dose 1a + Dose 2a and Ticagrelor Dose 1b + Dose 2b in Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease, sponsored by AstraZeneca. Completed at 18 sites in 6 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-12-14.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.
Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 210th largest by enrollment of the 559 interventional ones that give a count, is one of 36 that started in 2014, is one of 161 in phase 2, and was the 278th registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18–88
Mohsen Saidinejad · Sites in United States
Ages 5–20
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
Emory University · Sites in United States
Ages 8–18
University of Alabama at Birmingham · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
733 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 158 · Phase 2 228 · Phase 3 57 · Phase 4 20
First in 1984; this study’s year is marked. 36 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is above the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 31 across the 559 interventional studies, 100 across the 168 observational. Of the 506 that completed or were terminated, 207 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
168 of 733 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 7 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
57 of the studies in Anemia, Sickle Cell with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07247188Phase 3SanofiStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | 2027-01-07 |
| NCT04293185Phase 3bluebird bioA Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease | 2027-05 |
| NCT06989567Phase 3Asklepion Pharmaceuticals, LLCA Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis | 2027-06 |
| NCT05329649Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | 2027-06-06 |
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
Add all 57 to your calendar (.ics) → With an account.
Among the 733 studies in Anemia, Sickle Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase II dose-ranging study is to investigate pharmacokinetic (PK) and pharmacodynamic (PD) properties of various doses of ticagrelor followed by 4 weeks of twice-daily treatment in paediatric patients with sickle cell disease
This is a multicenter, open-label, dose-ranging study of ticagrelor followed by a double blind, placebo-controlled extension phase in paediatric patients with sickle cell disease (SCD).
Part A: Patients will be randomised 1:1 to receive one of two dosing schedules consisting of two single weight-adjusted doses of ticagrelor. Pharmacokinetic (PK) parameters and pharmacodynamic (PD) measurements will be determined following each dose. Platelet aggregation will be measured using the VerifyNow™ P2Y12 assay.
Following these 2 single doses, all patients will receive open-label one-week treatment with ticagrelor twice daily to determine tolerability prior to randomisation into Part B.
Part B: In this part patients will be randomised (2:1 ratio) to ticagrelor twice daily or placebo for a 4-week treatment phase.
During the study, patients will be followed for the occurrence of vaso-occlusive crisis (VOC) and for other disease manifestations such as daily pain, analgesic use and complications of SCD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week repeated dosing Part B: Ticagrelor or placebo 4 weeks repeated dosing.
Drug: Ticagrelor Dose 1a + Dose 2a
Part A: Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week repeated dosing. Part B: Ticagrelor or placebo 4 weeks repeated dosing.
Drug: Ticagrelor Dose 1b + Dose 2b
Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
P2Y12 Reaction Units (PRU) - Part A
Time frame: PRU measurements are taken in conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7) and after repeated dosing at Visit 4 (Day 14). Up to 8 hours post-dose (6 hours following protocol amendment) Visit 2 and 3, and up to 2 hours Visit 4.
P2Y12 Reaction Units (PRU) - Part B
Time frame: PRU measurements are taken after 4 weeks of double blind treatment at the end of Part B.
Maximum Plasma Concentration (Cmax) - Part A
Time frame: PK measurements (up to 8 hours post-dose) are taken in conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7) and after repeated dosing at Visit 4 (Day 14).
Maximum Plasma Concentration (Cmax) - Part B
Time frame: PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.
Area Under the Plasma Concentration Time Curve (AUC) - Part A
The PK parameter presented was derived using a model based analysis and not from a non-compartmental (NCA) analysis.
Time frame: PK measurements (up to 8 hours post-dose) are taken in conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7) and after repeated dosing at Visit 4 (Day 14).
Area Under the Plasma Concentration Time Curve (AUC) - Part B
The PK parameter presented was derived using a model based analysis and not from a non-compartmental (NCA) analysis.
Time frame: PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.
Assessment of Ticagrelor Concentration - Part A
Time frame: In conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7), after repeated dosing at Visit 4 (Day 14). Up to 8h post-dose (6h following protocol amendment, no pre-dose) Visit 2 and 3, up to 2h Visit 4 (pre-dose, 1h added following amendment)
Assessment of Ticagrelor Concentration - Part B
Time frame: PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.
Assessment of AR-C124910XX Concentration - Part A
AR-C124910XX is the active metabolite of Ticagrelor
Time frame: In conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7), after repeated dosing at Visit 4 (Day 14). Up to 8h post-dose (6h following protocol amendment, no pre-dose) Visit 2 and 3, up to 2h Visit 4 (pre-dose, 1h added following amendment)
Assessment of AR-C124910XX Concentration - Part B
AR-C124910XX is the active metabolite of Ticagrelor
Time frame: PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.
Oral Clearance (CL/F) - Part A
The PK parameter presented were derived using a model based analysis and not from a non-compartmental (NCA) analysis.
Time frame: PK measurements (up to 8 hours post-dose) are taken in conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7) and after repeated dosing at Visit 4 (Day 14).
Oral Clearance (CL/F) - Part B
The PK parameter presented was derived using a model based analysis and not from a non-compartmental (NCA) analysis.
Time frame: PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.
Number of Vaso-occlusive Crises - Part B
Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Number of Vaso-occlusive Crises Requiring Hospitalization or Emergency Department Visits - Part B
Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Percentage of Days Hospitalized for Vaso-occlusice Crisis or Other Complications of Sickle Cell Disease - Part B
Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Percentage of Days With Pain (Age >=4) - Part B
Pain measured using the Faces Pain Scale, range 0-10 (0, 2, 4, 6, 8, 10), where 0 is no pain
Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Mean Intensity of Pain (Age >=4) - Part B
Pain measured using the Faces Pain Scale, range 0-10 (0, 2, 4, 6, 8, 10), where 0 is no pain
Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Percentage of Days of Analgesic Use (Age >= 4) - Part B
Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Percentage of Days of Opioid Analgesic Use (Age >=4) - Part B
Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Percentage of Days of Absence From School or Work (Age >=6) - Part B
Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Haemorrhagic Events - Part A
Time frame: From randomisation to Part A (week 0) through Visit 4 (week 2)
Haemorrhagic Events - Part B
Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
The study was conducted at 24 centres, in 6 countries. The first patient was enrolled to Part A of the study on 11 Sep 2014, and the last patient completed Part B of the study on 27 Feb 2017. Recruitment was stopped due to protocol amendment between 8 September 2015 and 1 June 2016.
| Milestone | Part A - Ticagrelor | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|---|
| Started | 46 | 0 | 0 |
| Completed | 39 | 0 | 0 |
| Not completed | 7 | 0 | 0 |
| Withdrew: Patient decision | 2 | 0 | 0 |
| Withdrew: Dev. of study-specific withdrawal crit. | 4 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 |
| Milestone | Part A - Ticagrelor | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|---|
| Started | 0 | 17 | 8 |
| Completed | 0 | 14 | 7 |
| Not completed | 0 | 3 | 1 |
| Withdrew: Patient decision | 0 | 1 | 0 |
| Withdrew: Dev. of study-specific withdrawal crit. | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| P2Y12 reaction units | Ticagrelor 0.125 mg/kg | Ticagrelor 0.75 mg/kg | Ticagrelor 0.375 mg/kg | Ticagrelor 0.563 mg/kg | Ticagrelor 1.125 mg/kg | Ticagrelor 2.25 mg/kg | Ticagrelor 0.125 mg/kg Bid | Ticagrelor 0.563 mg/kg Bid | Ticagrelor 0.75 mg/kg Bid |
|---|---|---|---|---|---|---|---|---|---|
| Pre-dose | 301.6 ± 46.55 | 268.0 ± 35.95 | 295.4 ± 42.30 | 287.7 ± 34.35 | 283.7 ± 36.88 | 277.7 ± 39.36 | 320 ± NA | 205.4 ± 53.22 | 214.7 ± 48.71 |
| 2 hours post-dose | 278.2 ± 47.20 | 138.4 ± 70.68 | 229.0 ± 64.22 | 176.2 ± 79.53 | 128.9 ± 37.68 | 79.9 ± 47.74 | 271.2 ± 70.35 | 102.0 ± 72.53 | 152.0 ± 72.35 |
| 6 hours post-dose | 276.0 ± 75.43 | 189.0 ± 69.84 | 266.0 ± 57.98 | 190.4 ± 47.78 | 191.2 ± 57.59 | 141.7 ± 69.58 | — | — | — |
| 8 hours post-dose | 343.0 ± 38.13 | — | 318.3 ± 66.43 | 318.0 ± NA | — | — | — | — | — |
| P2Y12 reaction units | Ticagrelor 0.125 mg/kg Bid | Placebo |
|---|---|---|
| Pre-dose | 282.8 ± 19.26 | 313.3 ± 20.13 |
| 2 hours post-dose | 259.6 ± 61.95 | 217.3 ± 78.34 |
| ng/mL | Ticagrelor 0.125 mg/kg | Ticagrelor 0.75 mg/kg | Ticagrelor 0.375 mg/kg | Ticagrelor 0.563 mg/kg | Ticagrelor 1.125 mg/kg | Ticagrelor 2.25 mg/kg | Ticagrelor 0.125 mg/kg Bid | Ticagrelor 0.563 mg/kg Bid | Ticagrelor 0.75 mg/kg Bid |
|---|---|---|---|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) - Part A | 15.240 ± 15.2709 | 162.961 ± 84.9230 | 52.069 ± 34.4115 | 96.031 ± 51.4902 | 269.174 ± 162.2147 | 566.550 ± 225.9447 | 13.973 ± 15.3652 | 111.367 ± 81.1597 | 157.216 ± 114.8138 |
| ng/mL | Ticagrelor 0.125 mg/kg Bid |
|---|---|
| Maximum Plasma Concentration (Cmax) - Part B | 16.394 ± 13.3671 |
The PK parameter presented was derived using a model based analysis and not from a non-compartmental (NCA) analysis.
| ng*h/mL | Ticagrelor 0.125 mg/kg | Ticagrelor 0.75 mg/kg | Ticagrelor 0.375 mg/kg | Ticagrelor 0.563 mg/kg | Ticagrelor 1.125 mg/kg | Ticagrelor 2.25 mg/kg | Ticagrelor 0.125 mg/kg Bid | Ticagrelor 0.563 mg/kg Bid | Ticagrelor 0.75 mg/kg Bid |
|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Time Curve (AUC) - Part A | 161.9 ± 72.24 | 1151.9 ± 308.39 | 437.5 ± 262.24 | 879.3 ± 236.12 | 1638.7 ± 521.80 | 2850.9 ± 1277.39 | 161.9 ± 72.24 | 913.5 ± 208.82 | 1022.4 ± 287.32 |
The PK parameter presented was derived using a model based analysis and not from a non-compartmental (NCA) analysis.
| ng*h/mL | Ticagrelor 0.125 mg/kg Bid |
|---|---|
| Area Under the Plasma Concentration Time Curve (AUC) - Part B | 160.6 ± 88.58 |
| ng/mL | Ticagrelor 0.125 mg/kg | Ticagrelor 0.75 mg/kg | Ticagrelor 0.375 mg/kg | Ticagrelor 0.563 mg/kg | Ticagrelor 1.125 mg/kg | Ticagrelor 2.25 mg/kg | Ticagrelor 0.125 mg/kg Bid | Ticagrelor 0.563 mg/kg Bid | Ticagrelor 0.75 mg/kg Bid |
|---|---|---|---|---|---|---|---|---|---|
| Pre-dose | — | — | — | — | — | — | 2.170 ± NA | 31.937 ± 48.6501 | 28.066 ± 27.1344 |
| 1 hour post-dose | 12.713 ± 16.0627 | 104.243 ± 103.1502 | 34.069 ± 42.3746 | 33.294 ± 55.4258 | 182.558 ± 188.4254 | 390.568 ± 294.2189 | — | 80.414 ± 75.9675 | 151.520 ± 116.0079 |
| 2 hours post-dose | 11.465 ± 8.7427 | 107.729 ± 62.8343 | 37.782 ± 31.6890 | 74.626 ± 50.7053 | 162.435 ± 161.8489 | 426.804 ± 212.5385 | 13.973 ± 15.3652 | 102.166 ± 78.0785 | 101.618 ± 65.2415 |
| 4 hours post-dose | 6.647 ± 4.4533 | 75.907 ± 31.2786 | 20.122 ± 9.9383 | 51.005 ± 24.6435 | 118.217 ± 42.0873 | 188.383 ± 111.9267 | — | — | — |
| 6 hours post-dose | 3.663 ± 3.4061 | 52.966 ± 29.0297 | 19.435 ± 15.7259 | 45.502 ± 17.8950 | 69.708 ± 44.3168 | 125.279 ± 89.0005 | — | — | — |
| 8 hours post-dose | 3.880 ± 3.3171 | — | 15.699 ± 20.7596 | 15.691 ± 15.1392 | — | — | — | — | — |
| ng/mL | Ticagrelor 0.125 mg/kg Bid |
|---|---|
| Pre-dose | 2.478 ± 3.9580 |
| 1 hour post-dose | 9.677 ± 9.4275 |
| 2 hours post-dose | 14.144 ± 12.4711 |
| 4 hours post-dose | 9.605 ± 14.4979 |
AR-C124910XX is the active metabolite of Ticagrelor
| ng/mL | Ticagrelor 0.125 mg/kg | Ticagrelor 0.75 mg/kg | Ticagrelor 0.375 mg/kg | Ticagrelor 0.563 mg/kg | Ticagrelor 1.125 mg/kg | Ticagrelor 2.25 mg/kg | Ticagrelor 0.125 mg/kg Bid | Ticagrelor 0.563 mg/kg Bid | Ticagrelor 0.75 mg/kg Bid |
|---|---|---|---|---|---|---|---|---|---|
| Pre-dose | — | — | — | — | — | — | 1.250 ± NA | 17.380 ± 10.0399 | 20.359 ± 15.0788 |
| 1 hour post-dose | 1.782 ± 1.6604 | 16.302 ± 22.4614 | 4.577 ± 7.8610 | 3.708 ± 13.3332 | 30.070 ± 44.2950 | 63.088 ± 84.2091 | — | 24.945 ± 15.6547 | 43.986 ± 29.8127 |
| 2 hours post-dose | 2.681 ± 2.0733 | 33.256 ± 25.3854 | 11.757 ± 13.3322 | 15.918 ± 17.4849 | 52.932 ± 69.1056 | 149.772 ± 71.3624 | 4.026 ± 4.7624 | 37.013 ± 32.7650 | 44.690 ± 31.6577 |
| 4 hours post-dose | 2.071 ± 1.2770 | 29.860 ± 13.8726 | 7.630 ± 6.3730 | 17.015 ± 7.9272 | 50.887 ± 25.6964 | 101.370 ± 44.6207 | — | — | — |
| 6 hours post-dose | 1.646 ± 1.0427 | 25.276 ± 10.8318 | 9.762 ± 2.3304 | 16.703 ± 5.8115 | 35.716 ± 22.3351 | 76.941 ± 39.9167 | — | — | — |
| 8 hours post-dose | 1.715 ± 1.0226 | — | 6.176 ± 6.3168 | 9.232 ± 2.5385 | — | — | — | — | — |
AR-C124910XX is the active metabolite of Ticagrelor
| ng/mL | Ticagrelor 0.125 mg/kg Bid |
|---|---|
| Pre-dose | 1.810 ± 1.1213 |
| 1 hour post-dose | 2.865 ± 1.6443 |
| 2 hours post-dose | 4.160 ± 3.1503 |
| 4 hours post-dose | 3.953 ± 4.1179 |
The PK parameter presented were derived using a model based analysis and not from a non-compartmental (NCA) analysis.
| L/h | Overall |
|---|---|
| Oral Clearance (CL/F) - Part A | 22.50 ± 7.531 |
The PK parameter presented was derived using a model based analysis and not from a non-compartmental (NCA) analysis.
| L/h | Ticagrelor 0.125 mg/kg Bid |
|---|---|
| Oral Clearance (CL/F) - Part B | 19.15 ± 6.673 |
| Number of events | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|
| Number of Vaso-occlusive Crises - Part B | 1.0 ± 2.00 | 0.6 ± 0.74 |
| Number of events | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|
| Number of Vaso-occlusive Crises Requiring Hospitalization or Emergency Department Visits - Part B | 0.2 ± 0.41 | 0.1 ± 0.35 |
| Percentage of days | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|
| Percentage of Days Hospitalized for Vaso-occlusice Crisis or Other Complications of Sickle Cell Disease - Part B | 4.52 ± 11.816 | 1.34 ± 3.788 |
Pain measured using the Faces Pain Scale, range 0-10 (0, 2, 4, 6, 8, 10), where 0 is no pain
| Percentage of days | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|
| Percentage of Days With Pain (Age >=4) - Part B | 27.01 ± 34.065 | 31.78 ± 23.731 |
Pain measured using the Faces Pain Scale, range 0-10 (0, 2, 4, 6, 8, 10), where 0 is no pain
| Mean score on scale | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|
| Overall - Part B | 1.40 ± 2.027 | 0.87 ± 0.493 |
| 1st week | 1.64 ± 2.603 | 1.36 ± 0.827 |
| 2nd week | 1.11 ± 2.236 | 0.38 ± 0.525 |
| 3rd week | 1.06 ± 1.881 | 0.67 ± 1.116 |
| 4th week | 1.46 ± 2.624 | 0.83 ± 0.901 |
| Percentage of days | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|
| Percentage of Days of Analgesic Use (Age >= 4) - Part B | 16.79 ± 20.838 | 18.56 ± 19.110 |
| Percentage of days | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|
| Percentage of Days of Opioid Analgesic Use (Age >=4) - Part B | 12.46 ± 22.502 | 0.54 ± 1.537 |
| Percentage of days | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|
| Percentage of Days of Absence From School or Work (Age >=6) - Part B | 4.87 ± 10.865 | 5.95 ± 9.494 |
| Number of events | Part A - Ticagrelor |
|---|---|
| Haemorrhagic Events - Part A | 0 |
| Number of events | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|
| Haemorrhagic Events - Part B | 0 | 0 |
Collected over SAEs were collected from Visit 1 and AEs from Visit 2. SAEs and Other AEs are presented by study period, where Part A consists of the time from randomization to Part A through Visit 4. Part B starts the day after Visit 4 and continues until Visit 8.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A - Ticagrelor | 0/45 (0%) | 5/45 (11.1%) | 22/45 (48.9%) |
| Part B - Ticagrelor | 0/16 (0%) | 4/16 (25%) | 12/16 (75%) |
| Part B - Placebo | 0/7 (0%) | 1/7 (14.3%) | 5/7 (71.4%) |
| Event | Part A - Ticagrelor | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|---|
| Sickle cell anemia with crisisBlood and lymphatic system disorders | 3/45 | 3/16 | 1/7 |
| Acute chest syndromeRespiratory, thoracic and mediastinal disorders | 1/45 | 1/16 | 0/7 |
| Gastroenteritis viralInfections and infestations | 1/45 | 0/16 | 0/7 |
| Event | Part A - Ticagrelor | Part B - Ticagrelor | Part B - Placebo |
|---|---|---|---|
| Abdominal painGastrointestinal disorders | 6/45 | 3/16 | 2/7 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/45 | 4/16 | 2/7 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/45 | 3/16 | 2/7 |
| HeadacheNervous system disorders | 4/45 | 0/16 | 2/7 |
| VomitingGastrointestinal disorders | 0/45 | 3/16 | 0/7 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/45 | 3/16 | 0/7 |
| Sickle cell anemia with crisisBlood and lymphatic system disorders | 6/45 | 1/16 | 1/7 |
| GastritisGastrointestinal disorders | 0/45 | 0/16 | 1/7 |
| Facial painGeneral disorders | 2/45 | 1/16 | 1/7 |
| Non-cardiac chest painGeneral disorders | 2/45 | 1/16 | 1/7 |
The baseline characteristics are tabulated by the actual treatment group. This differs from the numbers in the Participant Flow since not all randomised patients received IP and one patient receiving treatment not matching the randomised treatment
| Age, Continuous(Years) | Part A - Ticagrelor | Part B - Ticagrelor | Part B - Placebo | Total |
|---|---|---|---|---|
| Mean | 11.2 ± 3.34 | — | — | 11.2 ± 3.34 |
| Age, Continuous(Years) | Part A - Ticagrelor | Part B - Ticagrelor | Part B - Placebo | Total |
|---|---|---|---|---|
| Mean | — | 10.2 ± 3.73 | 9.7 ± 3.35 | 10.0 ± 3.55 |
| Sex: Female, Male(Participants) | Part A - Ticagrelor | Part B - Ticagrelor | Part B - Placebo | Total |
|---|---|---|---|---|
| Female | 24 | 0 | 0 | 24 |
| Male | 21 | 0 | 0 | 21 |
| Sex: Female, Male(Participants) | Part A - Ticagrelor | Part B - Ticagrelor | Part B - Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 9 | 2 | 11 |
| Male | 0 | 7 | 5 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Part A - Ticagrelor | Part B - Ticagrelor | Part B - Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 44 | 0 | 0 | 44 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Part A - Ticagrelor | Part B - Ticagrelor | Part B - Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 0 | 15 | 7 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part A - Ticagrelor | Part B - Ticagrelor | Part B - Placebo | Total |
|---|---|---|---|---|
| White | 10 | 0 | 0 | 10 |
| Black or African American | 35 | 0 | 0 | 35 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part A - Ticagrelor | Part B - Ticagrelor | Part B - Placebo | Total |
|---|---|---|---|---|
| White | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 15 | 7 | 22 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2014 to primary completion in Feb 2017, 29 months.
Results were first posted in May 2018, 1 year 2 months after primary completion.
Of 34 industry-sponsored phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's 29 months is close to that.
Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.